Herbs (Global Traditional) · Ayurveda
Shyonak (Oroxylum indicum) (Oroxylum indicum)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Shyonak (Oroxylum indicum) is an Ayurvedic tree whose bark contains oroxin A, a bioactive compound that activates PPARγ receptors for blood sugar regulation. The plant demonstrates anti-inflammatory effects through modulation of inflammatory pathways in preclinical studies.
Shyonak (Oroxylum indicum) is a deciduous tree native to the Indian subcontinent and Southeast Asia, commonly found in tropical regions. The medicinal parts—primarily root bark, stem bark, seeds, leaves, and fruit—are traditionally extracted via decoction, powdering, or paste preparation in Ayurvedic practice. The plant contains key constituents including flavonoids (baicalein, chrysin, oroxin A) and anthraquinones (aloe-emodin).
No human clinical trials, RCTs, or meta-analyses were identified for Shyonak. Current evidence is limited to preclinical studies including in vitro antimicrobial and cytotoxic effects, and animal models demonstrating anti-inflammatory and anti-arthritic activity. A systematic review of ethnopharmacological data supports traditional uses but notes the absence of modern clinical trials.
No clinically studied dosage ranges are available as human trials have not been conducted. Traditional Ayurvedic use involves powdered root bark or stem bark as part of multi-herb formulations like Dashamoola, but specific quantities are not standardized in available sources. Consult a healthcare provider before starting any new supplement.
Shyonak (Oroxylum indicum) is primarily used as a medicinal herb rather than a dietary food source, so macronutrient data is limited; however, the following is documented: Bioactive flavonoids are the most extensively characterized constituents — baicalein (present in stem bark at approximately 0.1–0.5% dry weight), baicalin, oroxin A (oroxylin A-7-glucuronide), oroxin B, chrysin (5,7-dihydroxyflavone, ~0.2–0.8% in seeds and root bark), and scutellarein. Seeds contain fixed oils (approximately 20–25% by weight) rich in unsaturated fatty acids including oleic and linoleic acid. Tetuin (a flavone glycoside) and ellagic acid are present in the bark. Alkaloids including oroxindin are reported in minor concentrations (<0.1%). The stem bark contains tannins (~3–8% dry weight) and bitter principles contributing to its astringent profile. Mineral content is not well-characterized in standardized studies, though traditional preparations using bark decoctions would yield water-soluble phenolics and glycosides at biologically active concentrations. Dietary fiber content of bark powder is estimated at 15–25% dry weight based on structural carbohydrate composition. Protein content is low (<5% dry weight in bark). Bioavailability note: Oroxin A undergoes intestinal hydrolysis to release oroxylin A, which is the bioactive aglycone responsible for PPARγ activation; chrysin has limited oral bioavailability (~1%) in humans due to poor absorption and extensive conjugation, though co-administration with piperine has been shown to enhance absorption. Baicalein demonstrates moderate bioavailability with peak plasma concentrations achievable via decoction preparations.
Shyonak's primary bioactive compound oroxin A activates peroxisome proliferator-activated receptor gamma (PPARγ), improving glucose metabolism and insulin sensitivity. The root and stem bark contain flavonoids and phenolic compounds that inhibit pro-inflammatory cytokines like TNF-α and IL-6. Additional compounds including baicalein and chrysin contribute to respiratory support by relaxing bronchial smooth muscle.
Current evidence for Shyonak is limited to preclinical animal studies and in vitro research. Animal models using root and stem bark decoctions showed significant anti-inflammatory effects with reduced inflammatory markers. Laboratory studies demonstrated PPARγ activation by oroxin A, suggesting potential for prediabetes prevention, but human clinical trials are lacking. Traditional use supports respiratory benefits, though controlled human studies are needed to confirm therapeutic efficacy and optimal dosing.
Shyonak appears generally well-tolerated in traditional use, but comprehensive safety data is limited. The herb may potentiate blood sugar-lowering medications due to its glucose-regulating effects, requiring monitoring in diabetic patients. Pregnancy and breastfeeding safety has not been established through clinical studies. No specific drug interactions have been documented, but caution is advised when combining with anti-inflammatory medications or blood thinners.
